TILT Biotherapeutics Reports Publication on its Oncolytic Immunotherapy Platform in Pancreatic Cancer

Helsinki, Finland – 27 Aug 2021: TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, today announces that new preclinical data relating to the use of its oncolytic immunotherapy platform for expressing a human IL-2 variant protein has been published in Frontiers in Immunology (1). The paper was independently authored by researchers at the University of Helsinki (Finland) and other leading institutions, together with TILT Biotherapeutics.

Read the full release here.